Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: OTCMKTS:CYNAF
- CUSIP: N/A
- Web: N/A
- 52 Week Range: $8.00 - $19.52
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.24
- P/E Growth: 0
- Average Volume: 9,127 shs.
Frequently Asked Questions for Cynapsus Therapeutics (OTCMKTS:CYNAF)
What is Cynapsus Therapeutics' stock symbol?
Cynapsus Therapeutics trades on the OTCMKTS under the ticker symbol "CYNAF."
How were Cynapsus Therapeutics' earnings last quarter?
Cynapsus Therapeutics Inc (OTCMKTS:CYNAF) announced its earnings results on Wednesday, November, 12th. The company reported ($0.02) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.03) by $0.01. View Cynapsus Therapeutics' Earnings History.
Who are some of Cynapsus Therapeutics' key competitors?
Some companies that are related to Cynapsus Therapeutics include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT) and Axovant Sciences Ltd (AXON).
How do I buy Cynapsus Therapeutics stock?
Shares of Cynapsus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cynapsus Therapeutics' stock price today?
MarketBeat Community Rating for Cynapsus Therapeutics (OTCMKTS CYNAF)MarketBeat's community ratings are surveys of what our community members think about Cynapsus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cynapsus Therapeutics stock can currently be purchased for approximately $0.97.
Consensus Ratings for Cynapsus Therapeutics (OTCMKTS:CYNAF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cynapsus Therapeutics (OTCMKTS:CYNAF)Earnings History by Quarter for Cynapsus Therapeutics (OTCMKTS CYNAF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Current Year EPS Consensus Estimate: $-3.15 EPS
Next Year EPS Consensus Estimate: $-4.00 EPS
Dividend History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Latest Headlines for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Cynapsus Therapeutics (CYNAF) Chart for Wednesday, September, 20, 2017